Polymeric plerixafor: Effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection

Pharmaceutical Research

Volumn 31, Issue 12, 2014, Pages 3538-3548

  Wang, Yan ^a   Li, Jing ^a   Oupický, David ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CXCR4 antagonists; gene delivery; polyplexes; transfection

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DNA; DRUG VEHICLE; ETHIDIUM; HETEROCYCLIC COMPOUND; MACROGOL DERIVATIVE; PLERIXAFOR;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETIC TRANSFECTION; GENETICS; HUMAN; MEDICINAL CHEMISTRY; SIZE EXCLUSION CHROMATOGRAPHY; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; DNA; ETHIDIUM; HETEROCYCLIC COMPOUNDS; HUMANS; NEOPLASM INVASIVENESS; PHARMACEUTICAL VEHICLES; POLYETHYLENE GLYCOLS; RECEPTORS, CXCR4; TRANSFECTION;

EID: 84928367663     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1440-1     Document Type: Article

References (48)

1. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346-58.
2. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005;4(7):581-93.
3. Payne CK, Jones SA, Chen C, Zhuang X. Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic. 2007;8(4):389-401.
4. Hunter AC. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev. 2006;58(14):1523-31.
5. Zhou Q, Wu C, Manickam DS, Oupicky D. Evaluation of pharmacokinetics of bioreducible gene delivery vectors by real-time PCR. Pharm Res. 2009;26(7):1581-9.
6. Burke RS, Pun SH. Extracellular barriers to in vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver. Bioconjugate Chem. 2008;19(3):693-704.
7. Smith AE, Sizovs A, Grandinetti G, Xue L, Reineke TM. Diblock glycopolymers promote colloidal stability of polyplexes and effective pDNA and siRNA delivery under physiological salt and serum conditions. Biomacromolecules. 2011;12(8):3015-22.
8. Merdan T, Kunath K, Petersen H, Bakowsky U, Voigt KH, Kopecek J, et al. PEGylation of poly (ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice. Bioconjugate Chem. 2005;16(4):785-92.
9. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Buyens K, Sanders NN, et al. Stability of siRNA polyplexes from poly (ethylenimine) and poly (ethylenimine)-g-poly (ethylene glycol) under in vivo conditions: Effects on pharmacokinetics and biodistribution measured by fluorescence fluctuation spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Controlled Rel. 2009;138(2):148-59.
10. Oupicky D, Ogris M, Howard KA, Dash PR, Ulbrich K, Seymour LW. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther. 2002;5(4):463-72.
11. Oupicky D, Carlisle RC, Seymour LW. Triggered intracellular activation of disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic circulation in vivo. Gene Ther. 2001;8(9):713-24.
12. Walker GF, Fella C, Pelisek J, Fahrmeir J, Boeckle S, Ogris M, et al. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol Ther. 2005;11(3):418-25.
13. Fella C, Walker GF, Ogris M, Wagner E. Amine-reactive pyridylhydrazone-based PEG reagents for pH-reversible PEI polyplex shielding. Eur J Pharm Sci. 2008;34(4-5):309-20.
14. Brumbach JH, Lin C, Yockman J, Kim WJ, Blevins KS, Engbersen JFJ, et al. Mixtures of poly (triethylenetetramine/cystamine bisacrylamide) and poly (triethylenetetramine/cystamine bisacrylamide)-g-poly (ethylene glycol) for improved gene delivery. Bioconjugate Chem. 2010;21(10):1753-61.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
16. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3(6):453-8.
17. Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226(2):148-57.
18. Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther. 2010;9(6):409-16.
19. Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, Wald H, et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J of Immunol. 2006;177(10):6983-90.
20. Wald O, Izhar U, Amir G, Kirshberg S, Shlomai Z, Zamir G, et al. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg. 2011;141(6):1503-12.
21. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597-606.
22. Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003;22(50):8093-101.
23. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res. 2011;17(8):2074-80.
24. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1α. J Biol Chem. 2005;280(23):22473-81.
25. Guo P, You J-O, Yang J, Jia D, Moses MA, Auguste DT. Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm (2014)
26. Egorova A, Kiselev A, Hakli M, Ruponen M, Baranov V, Urtti A. Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells. J Gene Med. 2009;11(9):772-81.
27. Dong Y, Zhu Y, Li J, Zhou Q-H, Wu C, Oupický D. Synthesis of bisethylnorspermine lipid prodrug as gene delivery vector targeting polyamine metabolism in breast cancer. Mol Pharm. 2012;9(6):1654-64.
28. Dong YM, Li J, Wu C, Oupicky D. Bisethylnorspermine lipopolyamine as potential delivery vector for combination drug/gene anticancer therapies. Pharm Res. 2010;27(9):1927-38.
29. Li J, Zhu Y, Hazeldine ST, Li C, Oupicky D. Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion. Angew Chem Int Ed Engl. 2012;51(35):8740-3.
30. Li J, Oupicky D. Effect of biodegradability on on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric plerixafor. Biomaterials. 2014;35(21):5572-9.
31. Liu KK, Sakya SM, O'Donnell CJ, Flick AC, Li J. Synthetic approaches to the 2009 new drugs. Bioorg Med Chem. 2011;19(3):1136-54.
32. Li J, Zhu Y, Hazeldine ST, Firestine SM, Oupicky D. Cyclam-based polymeric copper chelators for gene delivery and potential PET imaging. Biomacromolecules. 2012;13(10):3220-7.
33. Hong CY, You YZ, Wu DC, Liu Y, Pan CY. Thermal control over the topology of cleavable polymers: from linear to hyperbranched structures. J Am Chem Soc. 2007;129(17):5354-5.
34. Fitzsimmons RE, Uludaʇ H. Specific effects of PEGylation on gene delivery efficacy of polyethylenimine: interplay between PEG substitution and N/P ratio. Acta Biomater. 2012;8(11):3941-55.
35. Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol. 2004;83(3):97-111.
36. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly (ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther. 2005;11(6):990-5.
37. Parhamifar L, Larsen AK, Hunter AC, Andresen TL, Moghimi SM. Polycation cytotoxicity: a delicate matter for nucleic acid therapy-focus on polyethylenimine. Soft Matter. 2010;6(17):4001-9.
38. Hong S, Leroueil PR, Janus EK, Peters JL, Kober M-M, Islam MT, et al. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjugate Chem. 2006;17(3):728-34.
39. Chen J, Hessler JA, Putchakayala K, Panama BK, Khan DP, Hong S, et al. Cationic nanoparticles induce nanoscale disruption in living cell plasma membranes. J Phys Chem B. 2009;113(32):11179-85.
40. Zhong Z, Feijen J, Lok MC, Hennink WE, Christensen LV, Yockman JW, et al. Low molecular weight linear polyethylenimine-b-poly (ethylene glycol)-b-polyethylenimine triblock copolymers: synthesis, characterization, and in vitro gene transfer properties. Biomacromolecules. 2005;6(6):3440-8.
41. Sung SJ, Min SH, Cho KY, Lee S, Min YJ, Yeom YI, et al. Effect of polyethylene glycol on gene delivery of polyethylenimine. Biol Pharm bull. 2003;26(4):492-500.
42. Hong JW, Park JH, Huh KM, Chung H, Kwon IC, Jeong SY. PEGylated polyethylenimine for in vivo local gene delivery based on lipiodolized emulsion system. J Control Release. 2004;99(1):167-76.
43. Casettari L, Vllasaliu D, Mantovani G, Howdle SM, Stolnik S, Illum L. Effect of PEGylation on the toxicity and permeability enhancement of chitosan. Biomacromolecules (2010)
44. Zhang X, Pan SR, Hu HM, Wu GF, Feng M, Zhang W, et al. Poly (ethylene glycol)-block-polyethylenimine copolymers as carriers for gene delivery: effects of PEG molecular weight and PEGylation degree. J Biomed Mater Res A. 2008;84(3):795-804.
45. Tang GP, Zeng JM, Gao SJ, Ma YX, Shi L, Li Y, et al. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials. 2003;24(13):2351-62.
46. Mersch-Sundermann V, Knasmuller S, Wu XJ, Darroudi F, Kassie F. Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology. 2004;198(1-3):329-40.
47. Uchida S, Itaka K, Chen Q, Osada K, Ishii T, Shibata M-A, et al. PEGylated polyplex with optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses. Mol Ther. 2012;20(6):1196-203.
48. Blessing T, Kursa M, Holzhauser R, Kircheis R, Wagner E. Different strategies for formation of PEGylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. Bioconjugate Chem. 2001;12(4):529-37.